Skip to Content
June, 22 2023

SteraMist – The Cutting-Edge Decontamination Technology Validated by the US Army 

As the world grapples with the ongoing challenges of decontamination, SteraMist has emerged as a pioneering solution. Developed by the Defense Advanced Research Projects Agency (DARPA), SteraMist has taken a remarkable journey, now culminating in validation by the United States Army for decontaminating toxoids. As noted in a recent press release, this groundbreaking achievement marks a significant milestone in the field of decontamination, promising improved safety and protection for military personnel and civilians alike. 

At the forefront of decontamination technology, SteraMist employs innovative ionized hydrogen peroxide (iHP) technology. This platform leverages a sole active ingredient of 7.8% hydrogen peroxide (H2O2) to create hydroxyl radicals that neutralize harmful microbes and toxins. These hydroxyl radicals are created after the solution is passed through a cold plasma arc. The resulting ionized mist effectively reaches inaccessible areas, ensuring thorough and comprehensive decontamination. The process also allows for no wet time which means an instant six log reduction of these microbes.  

DARPA’s SteraMist began its journey as a revolutionary concept designed to combat a wide range of biological agents and chemical threats, beginning with Anthrax. Over time, rigorous testing and development refined the technology, making it a potent tool for decontamination. Recognizing the immense potential of SteraMist, the United States Army partnered with TOMI to validate its effectiveness in neutralizing toxoids. The validation process involved extensive testing in controlled environments, simulating real-world scenarios encountered by military personnel. SteraMist successfully demonstrated its ability to eradicate harmful toxins, including Ricin, earning its validation as a trusted decontamination solution. 

The validation of SteraMist by the US Army holds immense significance for both military operations and civilian environments. In military settings, this breakthrough technology provides essential protection for troops in the event of chemical or biological attacks. By efficiently neutralizing toxoids, SteraMist can significantly reduce the risk of exposure and enhance the overall safety of military personnel. Beyond the military sphere, SteraMist’s validation also solidifies its application in various civilian settings. The technology can be employed to combat infectious diseases, sanitize public spaces, disinfect medical facilities, and support emergency response efforts. Its versatility and effectiveness make SteraMist a crucial asset in combating the spread of pathogens and safeguarding public health. 

SteraMist’s validation by the US Army underscores the ongoing commitment to advancing decontamination technologies. TOMI’s research and development efforts, coupled with the US Army’s rigorous testing and validation process, have paved the way for cutting-edge solutions in this critical field. As SteraMist gains recognition and adoption, it has the potential to reshape decontamination practices across various sectors. The technology’s ability to swiftly and effectively neutralize harmful toxins opens doors for enhanced safety measures and improved protection against chemical and biological threats. 

SteraMist is a revolutionary decontamination technology poised to make a lasting impact on military operations and civilian safety. Its Binary Ionization Technology platform combined with iHP technology, backed by extensive research and testing, sets the stage for advanced decontamination practices. With SteraMist’s effectiveness in neutralizing toxoids now established, we can look forward to a future where this cutting-edge solution plays a crucial role in protecting lives and ensuring the well-being of communities worldwide.  

Read the press release here and learn more about the technology behind this groundbreaking validation that can change the way the military can combat biological toxoids right here.